A Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled Dose-Ranging Study with Active-Controlled Long- Term Safety Phase to Assess the Efficacy, Safety and Tolerability of MK-6213 in Patients with Primary Hypercholesterolemia or Mixed Hyperlipidemia.

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled Dose-Ranging Study with Active-Controlled Long- Term Safety Phase to Assess the Efficacy, Safety and Tolerability of MK-6213 in Patients with Primary Hypercholesterolemia or Mixed Hyperlipidemia.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Oct 2015

At a glance

  • Drugs MK 6213 (Primary) ; Atorvastatin
  • Indications Hypercholesterolaemia
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 May 2011 New source identified and integrated (European Clinical Trials Database record EudraCT2007-003684-41).
    • 05 Feb 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top